Benefits of Bifidobacterium animalis subsp. lactis Probiotic in Experimental Periodontitis
- 2017-02
- Journal of Periodontology 88(2)
- L. Oliveira
- S. Salvador
- P. Silva
- F. Furlaneto
- L. Figueiredo
- R. Casarin
- E. Ervolino
- D. Palioto
- S. Souza
- M. Taba
- A. B. Novaes
- M. Messora
- PubMed: 27660886
- DOI: 10.1902/jop.2016.160217
Abstract
Background: This study evaluates effects of topical administration of probiotic bacteria of the genus Bifidobacterium on experimental periodontitis (EP) in rats.
Methods: Thirty-two rats were divided into groups C (control; without EP), EP (EP only), C-HN019 (control+probiotic), and EP-HN019 (EP+probiotic). On day 0 of the experiment, animals of groups EP and EP-HN019 received cotton ligatures around mandibular first molars (MFMs). In groups C-HN019 and EP-HN019, 1 mL of suspensions containing Bifidobacterium animalis subsp. lactis (B. lactis) HN019 was topically administered in the subgingival region of MFMs on days 0, 3, and 7. In groups C and EP, topical administrations were performed using a sham suspension (without probiotic). All animals were euthanized at day 14. Gingival tissue, hemimandibles, and oral biofilm were collected. Data were statistically analyzed (P <0.05).
Results: Group EP presented greater bone porosity, trabecular separation, and connective tissue attachment loss (CTAL) as well as reduced bone volume than all other groups (P <0.05). In group EP-HN019, there were greater proportions of Actinomyces and Streptococcus-like species and lower proportions of Veillonella parvula, Capnocytophaga sputigena, Eikenella corrodens, and Prevotella intermedia-like species than group EP. Group EP-HN019 presented greater expressions of osteoprotegerin and β-defensins than group EP (P <0.05). Group EP presented greater levels of interleukin-1β and receptor activator of nuclear factor-kappa B ligand than group EP-HN019 (P <0.05).
Conclusion: Topical use of B. lactis HN019 promotes a protective effect against alveolar bone loss and CTALs attributable to EP in rats, modifying immunoinflammatory and microbiologic parameters.
Keywords: Alveolar bone loss; Bifidobacterium; periodontal attachment loss; periodontitis; probiotics; rats.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium animalis subsp. lactis HN019 | Improved Connective Tissue Attachment Levels | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis HN019 | Improved Oral Microbiome Composition | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis HN019 | Increased Osteoprotegerin Expression | Beneficial | Moderate |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Alveolar Bone Resorption | Beneficial | Large |
| Bifidobacterium animalis subsp. lactis HN019 | Reduced Interleukin-1β Levels | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Altered Bacterial Proportions | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Increased Expressions of β-Defensins | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Increased Osteoprotegerin Expression | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Reduced Alveolar Bone Loss | Beneficial | Large |
| Bifidobacterium lactis HN019 | Reduced Connective Tissue Attachment Loss | Beneficial | Large |
| Bifidobacterium lactis HN019 | Reduced Interleukin-1β Levels | Beneficial | Moderate |
| Bifidobacterium lactis HN019 | Reduced Levels of Receptor Activator of Nuclear Factor-kappa B Ligand | Beneficial | Moderate |